TC
TGTX icon

Truvestments Capital’s TG Therapeutics TGTX Stock Holding History

Truvestments Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$96.9K Buy
1,764
+143
+9% +$5.85K 0.01% 408
2026
Q1 		$53.9K Hold
1,621
– – 0.01% 485
2025
Q4 		$48.3K Buy
1,621
+1,026
+172% +$33.5K 0.01% 456
2025
Q3 		$21.5K Buy
595
+135
+29% +$4.45K ﹤0.01% 584
2025
Q2 		$16.6K Buy
+460
New +$17.1K ﹤0.01% 569

Other funds holding TGTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return

Truvestments Capital's TGTX Position: Q2 2026 in Review

Truvestments Capital increased its TG Therapeutics (TGTX) stake by 8.8% in Q2 2026, buying an estimated $5.85K and bringing the position to 1,764 shares worth $96.9K. The position accounts for 0.01% of the portfolio, ranked #408.

Truvestments Capital first reported a position in TGTX in Q2 2025 and has held it in 5 quarters since. 431 funds tracked by Wall St. Rank hold TGTX as of Q2 2026.

  • Truvestments Capital held 1,764 shares of TG Therapeutics worth $96.9K as of Q2 2026.
  • Truvestments Capital bought 143 TG Therapeutics shares in Q2 2026, an estimated $5.85K.
  • TG Therapeutics made up 0.01% of Truvestments Capital's portfolio in Q2 2026, its #408 holding.
  • Truvestments Capital first reported a position in TG Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 431 funds tracked by Wall St. Rank held TG Therapeutics as of Q2 2026.

Based on Truvestments Capital's 13F filing for Q2 2026, filed 12 Aug 2026.